Advisors


  • WSGR website Conference Speakers Companies Dinner Interview Overview WSGR Website Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Conference Agenda Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Conference Agenda Conference Agenda Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Conference Speakers Companies Dinner Interview Overview WSGR Website Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Conference Agenda Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Conference Agenda Conference Agenda Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration Overview Conference Agenda Dinner Interview Conference Agenda Speakers Registration Dinner Interview Overview Conference Agenda Speakers Registration Dinner Interview Conference Agenda Speakers Registration

    Jim Alfaro
    Managing Director, Corporate Finance, Maxim Group
    New York, NY

    Otto Ankarcrona
    Vice President, Investor Growth Capital Europe,
    Stockholm, Sweden

    Hany Awadalla
    Managing Director, HSA Advisors, New York City, US

    Joseph E. Balagot
    Senior Managing Director, Investment Banking,
    Dawson James Securities, Inc., Boca Raton, US

    Erik Baas
    Former Director of Business Development, Medtronic,
    Geneva, Switzerland

    Daniel Bertholet
    Investment Director, Endeavour Vision
    Geneva, Switzerland

    David Biondo
    Vice President, P&M Corporate Finance
    Detroit, Michigan

    Joseph Cari Jr.
    Chairman and CEO, Castellini Partners
    New York City, US

    Jonathan I. Cope
    Managing Member, Lincoln Park Capital, Chicago, US

    Teo Dagi, MD
    Partner, HLM Venture Partners, Boston, MA

    James Datin Ph.D.
    Executive VP and Managing Director, Safeguard,
    El Paso, US

    Klaas de Boer
    Managing Partner, Entrepreneurs Fund, London, UK

    Anne De Gheest
    Managing Partner, MedStars Venture Partners
    Los Altos Hills, CA

    Mike DeVries
    Managing Director, EDF Ventures, Michigan, US

    Joseph DiTrolio, MD
    Roseland Surgical Center, Roseland, US

    Marco Elser
    CEO & Partner of Capital Markets, AdviCorp
    Rome, Italy

    Jon Garfield
    Chairman of the Advisory Board, OneMedPlace
    New York City, US

    Cecilia Gonzalo
    Managing Director, Warburg Pincus LLC,
    New York City, US

    Brett Johnson
    President, OneMedPlace, New York City, US

    Kimberly Ha
    Global Editor, BioPharm Insights, New York, NY

    James Huang
    Managing Partner, Kleiner Perkins Caufield & Byers China
    Shanghai, China

    Hervé de Kergrohen
    CEO, GlenBrook Ventures, Geneva, Switzerland

    Corinne Lebourgeios
    Managing Director, MedC. Partners, Aubonne, Switzerland

    Peter Leonardi
    Director, Five Prime Advisors, New York City, US

    Walter Lin
    Investment Director, Ascension Health Ventures,
    New York, NY

    Jeff Margolis
    President, Aurora Capital
    Saint Louis, US

    William McCluskey
    President and CEO, Brean Murray, Carret & Co,
    New York City, US

    J. Casey McGlynn
    Partner, Wilson Sonsini Goodrich & Rosati, California, US

    John Milad

    Investor, NBGI Ventures, London, UK

    Jeff Miller
    Vice President and Head of Healthcare, Capgemini,
    North Carolina, US

    Michael Nowak
    Managing Director and Head of Healthcare, Yorkville Advisors, New York, NY

    J. Misha Petkevich
    Co-Founder & Co-Managing Partner, BladeRock Capital, LLC
    Boston, US

    Antoine Papiernik
    Managing Partner, Sofinnova Partners, Paris, France

    Albert James Poliak
    President and CEO, Dawson James, Boca Raton, US

    Thom Rasche
    Partner, Earlybird Venture Capital, Hamburg, Germany

    Josh Scheinfeld
    Founder and Managing Member, Lincoln Capital, Chicago, IL

    Klaus Stöckemann
    Managing Partner, Peppermint Venture Partners, Berlin, Germany

    Pietro Strada
    Managing Director, Centerboard Partners Limited, London, UK

    Anthony Sun
    Partner, Aisling Capital, New York City, US

    James Tong, MD
    CFO, CBDO, and Board Director, Tianyin Pharmaceuticals
    China

    Don Urbanowicz
    Principal, Urbanowicz Consulting, LLC, New York City, US

    Geeta S. Vemuri
    Partner, Quaker BioVentures, Philadelphia, US

    Fred Zussa
    Managing Director, Health Digital Ventures, New York, NY

     

    Advisors Biographies

     

    Jim Alfaro
    Managing Director, Corporate Finance, Maxim Group, New York, NY

    Mr. Alfaro has over 12 years of experience in investment banking. Previous to joining Maxim, Mr. Alfaro was a Senior Vice President and Head of Healthcare Investment Banking at Wedbush Morgan Securities, a West Coast based full service investment bank. Mr. Alfaro began his career at Chase Securities (New York) in the firm’s Mergers & Acquisitions and Syndicated Finance groups and later joined J.P. Morgan’s Equity Capital Markets Group (New York). He holds an MBA from the University of California, Berkeley and participated in Berkeley’s exchange program with Columbia Business School and holds a B.A. from the University of Texas, Austin.

    [ Back to top ]

    Otto Ankarcrona
    Vice President, Investor Growth Capital Europe, Stockholm, Sweden

    Otto Ankarcrona joined Investor Growth Capital Europe in 2010 and is focused on investments in the Life Science sector. Before joining the Stockholm office Otto practiced medicine and served as Resident in Anesthesia and Intensive Care at Danderyd Hospital AB, a major hospital in the Stockholm area. He has a background in business development in the Life Science-sector through ScienceCap AB, a consultancy that he co-founded in 2000. He has held executive and board positions on several Life Science start-ups.
    Otto is a licensed physician and holds a Medical Degree from Karolinska Institutet and a M.Sc. from the Stockholm School of Economics, where he majored in Financial Economics.

    [ Back to top ]

    Hany Awadalla
    Managing Director, HSA Advisors, New York City, US

    Hany Awadalla is a Managing Director at HSA Advisors focusing on emerging growth Life Science companies. He has provided companies with financial and strategic advice for almost 25 years, He was responsible for Healthcare M&A at UBS, and was Head of Healthcare at Robertson Stephens and Wells Fargo. Most recently he was Head of Healthcare Investment Banking at Unterberg Towbin/Collins Stewart and FTN Equity Capital Markets. He has executed over 80 transactions valued over $10 billion in both Life Sciences and Healthcare Services. Hany received a BA in East Asian Studies and Economics from Columbia University and an MBA from the Wharton School, where he was also a Lauder Fellow with a focus on China.

    [ Back to top ]

    Joseph E. Balagot
    Senior Managing Director, Investment Banking, Dawson James Securities, Inc., Boca Raton, US

    Mr. Balagot is a seasoned investment banker with over 15 years of experience providing both financial and strategic advisory services to a broad array of clients ranging from start-up companies to mature operating companies. Mr. Balagot has successfully completed over 70 corporate finance transactions during his career with publicly announced transaction values totaling over $7 billion. His transaction record includes initial public offerings, follow-on public offerings, private placements, venture placements, mergers and acquisitions and strategic advisory assignments. Mr. Balagot joined Dawson James Securities, Inc. in October 2008 as a Senior Managing Director, Investment Banking and Head of Healthcare. Prior to joining Dawson James, Mr. Balagot had worked for three other Wall Street investment banks. Mr. Balagot was a member of Salomon Brothers investment banking teams in New York and London, England from 1994-1998. Mr. Balagot returned to the U.S. in 1998 and joined CIBC World Markets investment banking team in Menlo Park, California. Mr. Balagot left CIBC after six successful years to join San Francisco-based investment banking firm Merriman Curhan Ford as Managing Director, Head of Healthcare Investment Banking where he successfully financed several small cap healthcare clients during his three years prior to leaving to join Dawson James.

    [ Back to top ]

    Erik Baas
    Former director business development, Medtronic, Geneva, Switzerland

    Erik Baas was the former Director, Medicine and Technology, International at Medtronic where he was responsible for scouting for emerging technologies that will have an impact on Medtronic. In close partnership with Medtronic corporate and business units, he developed close collaborations with VC firms, technical universities in Europe and Israel and Medtronic’s diverse customer base. Erik Baas has worked within the biomedical, pharmaceutical, bioscience and IT fields where he has held roles in project management, business planning, and market development . His previous appointments have included the Netherlands Cancer Institute, Genencor International, Arthur D. Little, Geneva Bioinformatics, and Glaucus Proteomics. In 2002, Erik founded Arrante Bioscience in Holland, a company specialized in the development of protein biochips and production of various applications. Erik holds an MS in Biochemistry and Molecular Biology from the University of Amsterdam, a PhD in Biochemistry from the Free University of Amsterdam and an MBA from IMD in Lausanne.

    [ Back to top ]

    Daniel Bertholet
    Investment Director, Endeavour Vision, Geneva, Switzerland

    Daniel Bertholet is an Investment Director in the Life Sciences practice at Endeavour Vision, with a focus on medtech investments. Daniel has invested in Symetis, CeQur, Endoart (sold to Allergan), Thommen Medical (exited), Kuros Biosurgery, Novalar Pharmaceuticals and Neocutis. He also participated in investments and/or follow-on investments in Native Networks, eProject/Daptiv, Paion, Nexx Systems and Novimmune. Prior to his venture capital career, Daniel was the co-founder and CFO of a technology start-up and has invested as a business angel/private investor in private companies for over 15 years in Europe and the US. Daniel started his career as a consultant in country risk assessment for Business Environment Risk Intelligence (BERI) in the US and Switzerland.

    [ Back to top ]

    David Biondo
    Vice President, P&M Corporate Finance, Detroit, Michigan

    Mr. Biondo is a Vice President with P&M Corporate Finance. He is a member of the firm’s Medical Technology team, with extensive experience in orthopedics, specifically spine. Prior to joining PMCF, he served as a strategic consultant at Cameron Advisors, LLC where he advised several orthopedic start-up companies with M&A alternatives, capital raising efforts and expanding international distribution networks. Mr. Biondo served as a partner at Viscogliosi Brothers, LLC, concurrent with his position as Senior Vice President at Viscogliosi & Company, Inc. where he was responsible for facilitating capital raises for several spine and general orthopedic companies. Further, he was involved in numerous orthopedic acquisitions and licensing deals totaling more than $200 million, and served as Director of Corporate Finance for Paradigm Spine LLC. He was the principal researcher and author of the 2004 seminal spine non-fusion report “Beyond Total Disc: The Future of Spine Surgery”.
    Mr. Biondo earned a BA in Economics from the University of Michigan and is a FINRA licensed securities representative, holding his Series 7, 24, 63, and 79 registrations.

    [ Back to top ]

    Joseph Cari Jr.
    Chairman and CEO, Castellini Partners, New York City, US

    Joseph Cari Jr. is Chairman and CEO of Castellini Partners, an international merchant bank that focuses on the formation of joint ventures and investments in health care, media, financial services, alternative energy & technology. Mr Cari’s professional career has spanned the worlds of merchant banking, media, public policy,law and education. Mr. Cari is also the consultant to the American tv series “The Good Wife”.Mr. Cari has participated in the World Economic Forum in Davos, Switzerland and has been published on foreign policy issues by various publications including The Financial Times, Beirut Daily News and the Chicago Tribune. He currently sits on the Board of Directors of Amana Creative, Inc. and on the Advisory Board of One Medical Place LLC. In addition, Mr. Cari sits on the Advisory board of The World Policy Institute, the Advisory Boards of the Woodrow Wilson Center for International Scholars, Institute for Leadership Studies at Loyola Marymount University (Los Angeles), and as an Advisor to the American University Center for Global Peace (Washington, D.C.). Mr. Cari lectures on foreign policy and US presidential politics at the Lebanese American University (Beirut & Byblos), Loyola Marymount University (Los Angeles) and Villanova University. He is also a member of the Council on Foreign Relations (New York). Mr. Cari was appointed by U.S. President William Jefferson Clinton to be Chairman of the Board of the Woodrow Wilson Center for International Scholars; a federally funded Institute whose mission intersects the worlds of education, policy and politics. The Center works with various U.S. Federal Departments, such as State, Education and Commerce to provide insights on international issues from a social, religious, economic and political viewpoint. Chairman Cari played a key role in recruiting the Honorable Lee Hamilton as the CEO of the Center and supported Congressman Hamilton’s appointment to Co Chair the 9-11 Commission with former Secretary of State, James Baker. Chairman Cari was widely recognized for leading a Bi-Partisan Board, increasing funding for the Center and a strong working relationship with a Republican controlled Congress.

    [ Back to top ]

    Jonathan I. Cope
    Founder & Managing Manager, Lincoln Park Capital, Chicago, US

    Mr. Cope was a principal at Fusion Capital, a Chicago based fund where he worked for approximately 10 years helping to manage the Fund’s investments with an emphasis primarily in life sciences and technology companies. While working at a captive firm for Equity Group Investments (a Sam Zell investment arm), Mr. Cope focused on M&A, private equity and securities matters. Mr. Cope also practiced law at Katten Muchin Rosenman LLP. Mr. Cope holds a Masters degree in Molecular Biology, a J.D. from the University of Chicago and is a Phi Beta Kappa, Summa Cum Laude graduate in Economics from Brandeis University. Mr. Cope is a co-founder of an elementary school based in Chicago, and has sat on the Board of several Chicago based non-profit organizations.

    [ Back to top ]

    Teo Dagi, MD
    Partner, HLM Venture Partners, Boston, MA

    Prior to joining HLM in 2006, Teo was a Managing Partner of Cordova Ventures in Atlanta and oversaw its life sciences and health care portfolio. Before joining Cordova Ventures, Teo served as Principal at Access Partners in Westport, CT. Prior to that, he taught and practiced neurosurgery on the faculties of Harvard, Brown and Georgetown Universities, the Uniformed Services University of the Health Sciences and the National Institutes of Health. Teo currently serves as a director of IntelliDx and was previously a director of 14 publicly traded and privately held companies including: Atherogenics, Argos Therapeutics, Axela Biosensors and Inhibitex. He also is on the advisory board of Vengrowth, Oxford Finance Corporation, and sits on the steering committee of the Program in Biomedical Entrepreneurship of the Massachusetts Institute of Technology. Teo received an AB from Columbia College, an MD and MPH from Johns Hopkins, an MTS from Harvard, where he was a Joseph P. Kennedy, Jr. Fellow, and an MBA with distinction from the Wharton School. He trained in neurosurgery at the Massachusetts General Hospital and is a diplomat of the American Board of Neurological Surgeons.

    [ Back to top ]

    James Datin Ph.D.
    Executive VP and Managing Director, Safeguard Scientifics, Inc., El Paso, US

    As Executive Vice President and Managing Director of Life Sciences, Jim applies his broad industry knowledge to drive Safeguard’s partnership opportunities in Life Sciences. His significant experience as a marketing / sales and business development executive for leading pharmaceutical, medical device, diagnostics and software companies spans more than 20 years and covers assignments throughout the United States, Europe and Asia.

    [ Back to top ]

    Klaas de Boer
    Managing Partner, Entrepreneurs Fund, London, UK

    Klaas has more than 10 years of venture experience. It started when he created and led a corporate venturing team at Vanenburg Group whose investments included WebEx. Prior to this, he spent time as a consultant with McKinsey and Company in both Amsterdam and St Petersburg. Behind Klaas’ achievements are an MSc in Physics and an Insead MBA.

    [ Back to top ]

    Anne De Gheest
    Managing Director, MedStars Ventures, Los Altos Hills, CA

    Anne DeGheest is managing partner at MedStars Ventures Partners. Since 1986, she is a mentor capitalist specializing in investing and mentoring early-stage start-ups in healthcare. The life science companies for which she has been a founder or an early advisor have generated over $6 billion in market capitalization and have raised over $500 million in venture capital. She provided angel capital, hands-on operating expertise and/or business strategy in the founding of major companies like Pyxis (CareFusion), Aspect Medical (acquired by Covidien), VISX (acquired by AMO), Thermage (merged into Solta Medical), VISICU(acquired by Philips), Masimo (Nasdaq: MASI). She also helped grow new entrepreneurial division of large corporations like Johnson & Johnson, Baxter, Medtronic and McKesson. She was also part of the founding executive team of Nellcor (a division of Covidien), MedPool and OmniCell (Nasdaq: OMCL).

    Anne founded in 2010 HealthTech Capital, a group of private investors dedicated to funding and mentoring new “HealthTech” start ups at the intersection of healthcare and the computer/consumer electronic world. She is still an active investor with Life Science Angels, an angel group focusing on funding early stage medical devices and biotech start ups.

    She is on the board of directors of Immersion Corp. (Nasdaq: IMMR) and HealthTech Capital. She is an early investor, board observer and advisor to Pixel Optics, Visioneering and other early stage medical devices. She was an Entrepreneur-In-Residence with Institutional Venture Partners and started her career at Raychem after receiving an MBA from Harvard and a Master in Business Engineering from University of Brussels.

    [ Back to top ]

    Mike DeVries
    Managing Director, EDF Ventures, Michigan, US

    Mike’s 25-year medical device background, coupled with his experience with venture-backed companies, gives him a valuable perspective in guiding start-ups in the medical device industry. Currently, Mike sits on the boards of the following companies: Alure Medical, a company developing minimally invasive aesthetic surgery products; BioSurface Engineering Technologies, a developer of synthetic growth factors for medical devices; and CardioMetrix, a developer of endovascular sensor technologies used for the management of cardiovascular diseases. He serves as Chairman of the board for the following companies: Direct Flow Medical, a company developing percutaneous medical devices for cardiovascular diseases; Sonoma Orthopedic Products, a company developing novel orthopedic instrumentation; and TransCorp, Inc, a company that develops and commercializes novel minimally invasive surgical instruments and implants for neurosurgical and orthopedic applications. Prior to joining EDF, Mike served as President and CEO of A-Med Systems, a California-based cardiac device company. Prior to A-Med, Mike served on the executive team of Medtronic’s venture organization focused on cardiac surgery technology. His background also includes serving on the management team at DLP, a Michigan-based cardiac device company which was acquired by Medtronic. Mike holds an MBA from Grand Valley State University and a BA from Calvin College. In addition, Mike is a Kauffman Fellow.

    [ Back to top ]

    Joseph DiTrolio, MD
    Roseland Surgical Center, Roseland, US

    He is a graduate of the University of Richmond, University of Paris, Sorbonne and New Jersey Medical School. He is a Diplomate of the American Board of Urology and is well respected in the urology community for innovative techniques and product development. He is the holder of several Patents and is currently Clinical Professor of Surgery, Division of Urology at New Jersey Medical School, and the recent Past Chairman of the Department of Urology for the St. Barnabas Medical Center Healthcare System.

    [ Back to top ]

    Marco Elser
    CEO & Partner of Capital Markets, AdviCorp, Rome, Italy

    Marco Elser was born in Rome of an American father and Italian mother, then moved to New York City, only to return to Rome about 26 years ago. He received a Degree in Economics from Harvard in 1981. His professional experience includes being head of international market sales for Kinetix Measurements in New York, first vice president for Merrill Lynch Capital Markets in Rome and London, and head of international market and credit institutions sales for Northeast Securities in New York. Marco joined AdviCorp in 2002 where he set up its Capital Markets operations. Marco has been involved in the financial services field for over 25 years. He was a past Board member of National Icee Corporation, Porta Systems Inc, and currently Chairman of Universal Voltronics, a member of the Board of North Hills Signal and other private companies. He is specialised in restructurings and private placements; he and his firm have worked on a variety of transactions in healthcare, life sciences and medical technology, including Bracco Farmaceutici, Coventry Diagnostics, Orthovita, PhotoMedex, Cooper Sciences and Valeant. Marco is the President of the Harvard Club of Italy. He speaks English, Italian, French, and Spanish fluently. He is an active sportsman and is still competes in soccer, skiing and polo.

    [ Back to top ]

    Jon Garfield
    Chairman of the Advisory Board, OneMedPlace, New York City, US

    Jon has 20+ years of experience in running publicly traded and privately held companies. Most recently he was CEO of a public medical device company. Previously he was CFO of public and private companies and worked in Big 4 Public Accounting with PriceWaterhouseCoopers and Arthur Andersen.

    Jon was also the Co-Founder of a company that grew from concept to IPO to over $1Billion. Jon has raised more than $500 million in capital and led and completed more than 50 M&A transactions.

    Jon was recently appointed as Chairman of the Advisory Board for OneMedPlace healthcare conferences and is a Board of Director and Chairman of the Audit Committee of a publicly traded technology company. He is an EY Entrepreneur of the Year Semi-Finalist, CFO of the Year Finalist, and has frequently spoken at industry conferences and accounting groups.

    Jon is currently actively seeking a new management opportunity with a midsize public or private company.

    [ Back to top ]

    Cecilia Gonzalo
    Managing Director, Warburg Pincus LLC New York City, US

    Cecilia Gonzalo joined Warburg Pincus in 2001 and focuses on investments in the biotechnology, pharmaceuticals and healthcare services sectors. Prior to joining Warburg Pincus, Ms. Gonzalo worked at Goldman Sachs in the Investment Banking Division focusing on corporate finance and mergers and acquisitions transactions in Latin America, as well as in the Principal Investment Area focusing on investments in the region. She received a B.A. cum laude, in Biochemical Sciences from Harvard College and an M.B.A. from Harvard Business School. Ms. Gonzalo is a director of Rib-X Pharmaceuticals.

    [ Back to top ]

    Brett Johnson
    President, CEO and Founder, OneMedPlace, New York City, US

    Brett is an experienced entrepreneur, having successfully launched numerous communications-related enterprises. He started with the Minnesota Collaborative a regional network that assists emerging companies and annually hosts one of the country’s largest venture capital conferences, where presenting companies have raised in excess of $2 billion since 1994. He was founder and editor-in-chief of Minnesota Ventures magazine, a regional business publication focusing on small and growing companies. He was also founder and publisher of Law & Politics magazine, a monthly published in Minnesota and Washington and whose SuperLawyers supplement is syndicated in 40 markets. His healthcare experience began in pharmacy, where he worked with the National Community Pharmacists Association NCPA and founded Cornerdrugstore.com. There, as CEO, he built an online network of almost 2,000 local drugstores throughout the U.S. He was also active in the financing and development of Health Integrated, a leading national disease management company. His non-profit background includes founding the Environmental Initiative in 1990 to address regional environmental issues by bringing together environmental groups, industry and government. The organization has become a model for other regional environmental initiatives. He received his degree in economics from Harvard University.

    [ Back to top ]

    Kimberly Ha
    Global Editor, BioPharm Insights, New York, NY

    Kimberly Ha is Global Editor for BioPharm Insight, an independent business intelligence product launched by the Financial Times Group. She manages all editorial content and generates daily breaking news coverage. Kimberly has been with Mergermarket since 2005 covering healthcare. She started out as a financial journalist in Hong Kong specializing in healthcare M&A, and was the lead sector specialist before transferring to New York to launch this product in 2007. Kimberly has been a sought-after panelist and moderator at major healthcare investor conferences and events, including the Prix Galien Awards. In 2011, based on her extensive coverage of Alzheimer’s disease, she was nominated by the Alzheimer’s Association and was ultimately selected to be a National Press Foundation Fellow. Kimberly has a BA in Psychology from New York University. She is fluent in Cantonese, Shanghainese, and is proficient in Mandarin.

    [ Back to top ]

    James Huang
    Managing Partner, Kleiner Perkins Caufield & Byers China,
    Shanghai, China

    James Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies.

    Before coming to KPCB China, James was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).

    James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.

    [ Back to top ]

    Hervé de Kergrohen
    CEO, GlenBrook Ventures, Geneva, Switzerland

    Hervé de Kergrohen is a medical doctor with broad industry knowledge. After taking his MBA degree from Insead, Fontainebleau in 1991, he held several positions in R&D and marketing areas for international pharmaceutical groups. From 1995 to 2000, he was manager of public equity health care funds. Since 2000, he has been investing in private equity in the life science sector in the US and in Europe. He is currently Venture Partner with CDC Entreprises Innovation and board member of several public and private companies. As Chairman of Kergrohen&Associates, a swiss company dedicated to Corporate Communication and Public Relations specialized in Life Science markets, Hervé built up the concept of BioData in April 2001 and is then its Founder, Chairman, as well as head of its Organizing Committee.

    [ Back to top ]

    Corinne Lebourgeois
    Managing Director, MedC. Partners, Aubonne, Switzerland

    Graduate in Sciences (B.Sc.) and Business (MBA), Corinne Lebourgeois started her career in 1989 as Product specialist with W.L.GORE & Associates where she managed the non cardiovascular surgical product line and developed the aesthetic surgery market.
    Corinne joined ETHICON, a Johnson & Johnson division, in 1992 as Senior R&D Manager in charge of the product development department. Her main responsibilities included product evaluation from concept screening to clinical trials management. She worked in different therapeutic fields such as orthopaedics, cardiac surgery, open and endoscopic general surgery and successfully CE marked new products.
    In 1995 she also acted as Lead Marketing Manager for Ethicon meshes business in Europe and supervised MITEK product marketing activity in France.
    In 1997 Corinne was directly involved in the creation of GYNECARE, the new Women’s Health division of J&J, sole responsible of the Marketing. She built Gynecare uro-gyneco market in France from scratch, managing operational and strategic marketing that led to multimillion euros successes. She also initiated the Direct To Patient communication strategy in order to educate patients with “taboo conditions” such as incontinence and menorrhagia.
    Corinne moved to the US in 2000 where she worked as an independent Marketing Consultant for start up companies (Acueity Inc, Contura, Navion Inc) and Non Profit (Asthma Care Center) and corporations (Gynecare, Clinical Device Group, Dey Inc) where she developed European market entry strategies successfully. In 2002, she also graduated in “E Business and Technology” from UC Berkeley where she studied the new economy with an emphasis in “e Marketing” and “Crafting for e Business Models” and where she was introduced to the venture capital community.
    Back in Europe in 2003, Corinne set up her consultancy business in Switzerland where she continues to support SMEs and start-ups in their marketing and business development activities.
    In 2005, Corinne found MC Medical Consultant Partners Sarl in Aubonne and partnered with Marie José Plique to further develop her consulting activities. Nowadays, they work under the MedC.PartnersTM brand name.

    [ Back to top ]

    Peter Leonardi
    Director, Five Prime Advisors, New York City, US

    Prior to joining Five Prime Advisors, Dr. Leonardi led the business development and technology transfer program at New York Presbyterian Hospital, the University Hospital of Columbia and Cornell, where he helped found and incubate several medical device and healthcare information technology companies. While there, he oversaw technology out-licensing. Dr. Leonardi has consulted to many top biotechnology and healthcare firms and Tier-I venture capital funds. Dr. Leonardi received his Ph.D. from the New York University School of Medicine, where he was a National Cancer Institute trainee. He received his M.B.A. from Carnegie Mellon University, where he was a T. Jerome Holleran Fellow. He received a B.S. and M.S. from the University of Connecticut and attended the United States Air Force Academy. Dr. Leonardi serves as a Columbia Business School Entrepreneurship Mentor and is an advisor to the school’s Lang Fund. He also serves as a Global Social Venture judge at the Columbia Business School.

    [ Back to top ]

    Walter Lin
    Investment Director, Ascension Health Ventures, Saint Louis, US

    Walter Lin joined AHV in 2007 from Catholic Healthcare West, where he served as the corporate Director of Clinical Innovations. Walter is primarily focused on investments in the medical device sector and is a board member at AHV portfolio companies Cheetah Medical, Sonoma Orthopedic Products, and Vascular Pathways and a board observer at EKOS Corporation. At Catholic Healthcare West, he led a team focused on improving quality and decreasing costs by minimizing unnecessary variation in clinical practice patterns. He is a board-certified internist and maintains a part-time clinical practice in emergency medicine. Walter holds a Doctor of Medicine from the University of California, San Francisco, a MBA from the Wharton School of Business at the University of Pennsylvania, a MS from the University of California, Berkeley and a BAS in Economics and Biology from Stanford University. He completed his training in Internal Medicine at Yale New Haven Hospital.

    [ Back to top ]

    Jeff Margolis
    President and founder of Aurora Capital LLC, Mr. Margolis founded Aurora in October 1994. Aurora Capital Corp. was registered with the SEC and became a member of the FINRA (formerly NASD) in May 1995. Aurora Capital LLC succeeded to the business of Aurora Capital Corp. on September 16, 1998.

    In 2004, Jeff began expanding the firm’s capabilities and founded Atypical BioCapital Management LLC (Atypical Bio(tm)) and Atypical BioVentures Fund LLC, a life science fund management company and venture fund respectively. Atypical Bio(tm) also manages a micro cap and small cap public life science portfolio for a fund-of-funds. The Atypical Bio(tm) group is an affiliate of Aurora.

    Prior to founding Aurora, Jeff was at D. Blech & Company Incorporated from 1992 until 1994, an investment banking firm specializing in biotechnology companies.

    Before joining D. Blech & Company, Mr. Margolis worked for nearly a decade for the Fundamental Brokers Group, an international affiliated group of fixed income securities brokers. His last position with the firm was chief financial officer. He holds the following securities industry registrations: (i) general securities principal (Series 24), (ii) registered representative (Series 7), (iii) state agent (Series 63), (iv) financial and operations principal (Series 27), (v) municipal securities principal (Series 54), (vi) options principal (Series 4).

    [ Back to top ]

    William McCluskey
    President and Chief Executive Officer, Brean Murray, Carret & Co., LLC, New York City, US

    Brean Murray is a 40 year old New York based investment bank and money management firm that completed over 600 transactions for companies throughut the world in aggregate several
    billion dollars with offices in throughout the US and Beijing and Shanghai. Mr. McCluskey and BMC are widely recognized as leading experts in financing and advising Chinese companies having completed over 40 transactions for over $2 billion. Prior to joining BMC in 2002, Mr. McCluskey was the Senior Managing Director of Gruntal & Co. LLC, a New York Stock Exchange member firm. Prior to Gruntal, he was Chief Executive of Henry Ansbacher, Inc. a leading London based international merchant bank and part of the Ansbacher Group, which was publicly traded on the London Stock Exchange. Mr. McCluskey began his career with the Hong Kong Shanghai Marine Midland Banking Group where he spent five years completing over 40 transactions and managing a loan portfolio in excess of $2 billion.

    [ Back to top ]

    J. Casey McGlynn
    Partner, Wilson Sonsini Goodrich & Rosati, California, US

    Casey McGlynn is a partner at the law firm of Wilson Sonsini Goodrich & Rosati. He serves as a member of the board of directors and, since joining the firm in 1978, he has been a member of the firm’s Policy, Nominating, and Compensation Committees. Casey’s practice focuses on the organization, funding, and corporate representation of companies in the information technology, life sciences, and telecommunications industries. He is a nationally recognized leader in the representation of start-up and growth technology companies. Casey assists his clients in meeting their financing needs through introductions to an extensive network of angel investors, financiers, venture capitalists, corporate partners, and investment bankers. He has experience representing dozens of companies that have made successful initial public offerings and secondary offerings. He frequently is called upon to structure and negotiate mergers and acquisitions, licensing arrangements, and domestic and international strategic corporate alliances, as well as other innovative financing arrangements. Casey is a frequent speaker and written contributor on issues relating to the organization and funding of new ventures. He was recognized in the 2005-2010 editions of Chambers USA: America’s Leading Lawyers for Business for “his life sciences, information technology, and telecom expertise.” Casey received his J.D. and B.A. degrees, with highest honors, from Santa Clara University. He is admitted to practice in California.

    [ Back to top ]

    John Milad

    Investor, NBGI Ventures, London, UK

    John brings to NBGI Ventures an extensive track record in healthcare corporate finance and private equity. He joined from Insight Capital, which he founded to provide fundraising, strategy and M&A advisory services to life sciences companies and investors. John’s previous roles include Special Advisor to Atlas Venture, Interim CFO at Nitec Pharma, and Associate Director at Nomura International plc, where he was involved in a number of high profile transactions. John started his career as an investment banker at Lehman Brothers, followed by three years at Kirkland Investors. John holds a BA in Political Science from University of Chicago.

    [ Back to top ]

    Jeff Miller
    Vice President and Head of Healthcare, Capgemini, North Carolina, US

    A dynamic leader focused on identifying, developing, and implementing innovative business organizations, Jeff is Vice President and lead for Capgemini’s Healthcare business in North America. In this role he is responsible for market strategy, business planning, service offerings, and solutions development for the healthcare sector. His current focus includes the development of information technologies to support personalized medicine, the definition of analytical models for healthcare markets, and the creation of utility models to support cloud-based health services.

    [ Back to top ]

    Michael Nowak
    Managing Director and Head of Healthcare, Yorkville Advisors, New York, NY

    Michael J. Nowak is a Managing Director at Yorkville Advisors and has been with the Firm since 2007. He leads the Firm’s Healthcare Investment Team with over 20 years of experience in the early-stage financing of innovative high technology companies. He has led over two dozen investments in public Life Sciences companies listed on over 10 exchanges around the world during the last four years at the Firm.
    Prior to joining Yorkville Advisors, Michael was a General Partner at TVM Capital, a billion dollar Euro-US venture fund. He also has entrepreneurial, business development and investment experience from work as a co-founder of the Xerox Venture Lab at Xerox PARC, as a Vice President of Business Development for an emerging high tech consulting practice at McKinsey & Co., and as a manager of two $100 million investment programs at the Advanced Technology Program at the National Institute of Standards and Technology, US Department of Commerce.
    Michael earned an MBA from the Wharton School at the University of Pennsylvania and a PhD in Physics from the University of California, Santa Barbara. He worked as a post-doctoral scientist at Bell Labs (Bellcore), Princeton University, and at the CEA research labs in Saclay, France. He received his BA in Physics from Cornell University in Ithaca, NY, where he was a College Scholar.

    [ Back to top ]

    J. Misha Petkevich
    Co-Founder & Co-Managing Partner, BladeRock Capital, LLC. BladeRock Capital, Boston, US

    J. Misha Petkevich is co-founder and co-managing partner of BladeRock Capital, LLC. BladeRock Capital was formed in 2006 and currently manages the V2M® Life Sciences fund. Prior to founding BladeRock, Mr. Petkevich was Chairman and Chief Executive Officer of The Petkevich Group, LLC, a boutique merchant bank serving and investing in information technology and healthcare companies. From 1989 until 1997, Mr. Petkevich was a Managing Director at Robertson, Stephens & Co. During that time, he held various positions including Head of Investment Banking, Head of Healthcare Banking, and a member of the Management Committee, the Commitment Committee and the Fairness Opinion Review Committee. Prior to Robertson Stephens, he held positions as an Institutional Investor ranked securities analyst and as an investment banker at Hambrecht & Quist and worked closely with the life sciences venture group. Throughout his career on Wall Street, Mr. Petkevich executed directly or managed other bankers on nearly 700 financing and merger and acquisition transactions with a value of over $65 billion. Prior to Wall Street, he served as a color commentator for CBS, NBC, and ESPN. He is currently on the Board of Trustees of the United States Figure Skating Foundation and the Friends of the King Hussein Institute for Biotechnology and Cancer and is on the Advisory Board of the Gladstone Institute. Mr. Petkevich received an AB degree from Harvard College, attended Oxford University as a Rhodes Scholar where he was awarded a Doctorate in Cell Biology. While at Harvard, he created “An Evening with Champions” in 1970, a skating exhibition in which world class skaters performed and which Harvard students organized to raise money for the Dana Farber Cancer Research Foundation. 2010 represented the 40th Anniversary of the event. Following Oxford, Mr. Petkevich studied music privately, was a Fellow in the Music Department at Harvard and was Composer in Residence at Eliot House, Harvard University where some of his compositions were premiered. He represented the United States in the 1968 and 1972 Winter Olympics and was United States, North American, and World University Games Figure Skating Champion. Mr. Petkevich has been inducted in the USFSA Hall of Fame and has written two books on figure skating.

    [ Back to top ]

    Albert James Poliak
    President and CEO, Dawson James, Boca Raton, US

    Mr. Albert James Poliak is employed at Dawson James Securities, Inc. in the position of Chief Executive Officer and President. Mr. Poliak has over 20 years of experience in the securities industry holding various management positions including President and Chief Executive Officer, Head of Trading, Regional Sales Manager, Branch Manager and Chief Compliance Officer. Mr. Poliak is a co-founder of Dawson James Securities. Mr. Poliak has been responsible for overseeing all daily activities of several brokerage firms including trading, market making, compliance, operations, underwriting & syndication, financial compliance and all general brokerage services.

    [ Back to top ]

    Antoine Papiernik
    Managing Partner, Sofinnova Partners, Paris, France

    Antoine Papiernik is a Managing Partner at Sofinnova Partners in Paris. He invests in life sciences. He joined Sofinnova Partners in 1997, and was previously with CDC-Innovation, the venture arm of the Caisse des Dépôts group. Since joining Sofinnova Partners, Antoine has been an initial investor and active board member in companies like Actelion, Addex, Orexo and NovusPharma, which went public respectively on the Zürich stock exchange, the Stockholm stock exchange and the Milan Nuovo Mercato, in Cotherix (initially NASDAQ listed, then sold to Actelion) and CoreValve (sold to Medtronic). He has also invested in and is a board member of CoAxia, EOS, Fovea, Lectus, Movetis, SpineVision and Stentys. He has an MBA from the Wharton School of Business, University of Pennsylvania.

    [ Back to top ]

    Thom Rasche
    Partner, Earlybird Venture Capital, Hamburg, Germany

    Thom Rasche joined Earlybird as a Venture Partner in 2003 and was promoted to Partner in 2006. He is a seasoned executive in the medical device and diagnostic sectors with over 20 years of operational experience.

Since he joined Earlybird, Thom has been responsible for the medical device portfolio and for making new investments in this area. He has successfully led various financing rounds in both European and US based medical device companies before the investment in Miracor.

Thom is on the board of Zonare Medical Systems and has held various senior marketing and sales positions with Johnson & Johnson in Europe and the US. Thom Rasche holds a Degree as Diplom Kaufmann (MBA equivalent) from the University of Applied Sciences in Lüneburg, Germany, specializing in marketing and human resource management.

    [ Back to top ]

    Josh Scheinfeld
    Founder and Managing Member, Lincoln Capital, Chicago, IL

    Mr. Scheinfeld was a founder and Managing Member of Fusion Capital, a Chicago based investment fund started in 1999 that has funded or committed to fund over $700 million. In addition, Mr. Scheinfeld is a serial entrepreneur and has extensive experience in starting, running and raising capital for public and private companies as well as real estate ventures. While a management consultant at McKinsey & Company, Inc., he was part of teams that solved business problems for Fortune 500 companies. Mr. Scheinfeld practiced law at the Chicago law firm of Katten Muchin Rosenman LLP where he specialized in corporate acquisition, securities and venture capital transactions. Mr. Scheinfeld received his Juris Doctor, Cum Laude, from Harvard Law School. Mr. Scheinfeld graduated Phi Beta Kappa with a BA in Economics and Distinction in all Subjects from Cornell University.

    [ Back to top ]

    Klaus Stöckemann
    Managing Partner, Peppermint Venture Partners, Berlin, Germany

    Klaus is Managing Partner & Co-Founder of Peppermint VenturePartners which recently launched the Charité Biomedical Fund. Before this he was a General Partner in 3i`s international Healthcare Venture Team. He has more than 12 years Pharma experience with leading roles at Schering AG and ASTA Medica a Degussa&Hüls group company in R&D and Business Development. He holds a Ph.D in Biology and Pharmacology from the University of Mainz as well as a MBA from WHU / Kellogg Northwestern University in the US. Klaus has more than 12 year of experience in the Venture Capital Industry and was on 3i’s side responsible for many investments and IPO’s including Epigenomics. Jerini, Santhera as well as the trade sales of Evotec Neuroscience, Amaxa and Elbion. Klaus has been board member of Combinature, Epigenomics, Jerini, Elbion, Evotec Neuroscience, Amaxa, Immatics as well as IntelliDx and Zonare in the US. He focuses on Medical Devices and special Pharma investments. He currently is chairman of the boards of Humedics and Hematris Wound Care.

    [ Back to top ]

    Pietro Strada
    Managing Director, Centerboard Partners Limited, London, UK

    During the last 10 years Pietro has advised or acted as principal on over 20 completed financial transactions. Prior to founding Centerboard he was Strategy & Business Development Director with a division of Reed Elsevier. Pietro has successfully broadened Centerboard sector focus into the med-tech, advising leading companies that satisfy unmet medical needs with innovative or disruptive products. Formerly Pietro was a Principal at Broadview where for 5 years he covered the communications technologies and semiconductor sectors and led the execution of deals including cross-border mergers and acquisitions, fund-raisings and public takeovers. Prior to Broadview, Pietro was a consultant with Bain & Co. and earlier an electronic R&D engineer with OHB System and Italtel. He holds an MBA degree from INSEAD and an MS degree in electrical engineering from Politecnico di Milano. Speaks Italian, French and German.

    [ Back to top ]

    Anthony Sun
    Partner, Aisling Capital, New York City, US

    Dr. Sun joined Fund I in 2002 and currently serves as a Partner. Previously, Dr. Sun was an Adjunct Instructor of Medicine at the Hospital of the University of Pennsylvania. 

Dr. Sun currently serves as a director of CeNeRx BioPharma, Inc., Dynova Laboratories, Inc., HerbalScience, Inc., and Paratek Pharmaceuticals, Inc. Previously he served as a director of MAP Pharmaceuticals, Inc. 

Dr. Sun received his M.D. from Temple University School of Medicine with A.O.A. honors. He received his M.B.A. from The Wharton School at the University of Pennsylvania, and his B.S. in Electrical Engineering from Cornell University. In addition, he is Board Certified in Internal Medicine.

    [ Back to top ]

    James Tong, MD
    CFO, CBDO, and Board Director, Tianyin Pharmaceuticals, China.

    James Jiayuan Tong MD, PhD. is CFO, CBDO and Board Director of Tianyin Pharmaceuticals (NYSE Amex: TPI), headquartered at Chengdu, China. Prior to joining Tianyin in 2010, Dr. Tong was the Head of China Healthcare Investment Banking at ROTH Capital and before that a biotechnology analyst at Rodman & Renshaw. Prior to his Wall Street career, he was Principal Investigator at Marine Biological Laboratory at Woods Hole, MA and a Senior Research Fellow at University of California, Irvine. Dr. Tong was awarded Ph.D. in Neurobiology and Behavior from Cold Spring Harbor Laboratory / Stony Brook University Neuroscience program where he developed an innovative method to significantly extend life spans of animals based on his work on mitochondria, aging and learning disorders in Neurofibromatosis-1 (NF1) disease. He published three first-authored Nature articles and currently holds two patents. Dr. Tong received his medical degree from Peking University Health Science Center.

    [ Back to top ]

    Don Urbanowicz
    Principal, Urbanowicz Consulting, LLC, New York City, US

    Don Urbanowicz, UC’s principal, has a 30 year track record in the healthcare industry, with a deal-making focus over the past ten years. Don has held prior senior management/leadership positions at Stryker, Smith & Nephew, Sofamor Danek and Aircast. He has successfully developed and implemented strategic planning and business development transaction life cycle processes. He has also successfully concluded numerous pre-revenue and bolt-on transactions, many of which were outside the U.S. Don has a deep understanding of how strategics think about, approach and place value on potential transactions.

    [ Back to top ]

    Geeta S. Vemuri
    Partner, Quaker BioVenture, Philadelphia, US

    Dr. Geeta S. Vemuri is a Partner at Quaker BioVentures. Dr. Vemuri has been a Partner with the firm since 2008. She joined the firm as a Senior Associate in 2003 and was promoted to a Vice President in 2005. Previously, Dr. Vemuri was an Associate at Toucan Capital Corp., where she was responsible for investments in seed-stage and start-up biotech opportunities. At Toucan, Dr. Vemuri participated in raising the capital for Toucan Fund II from the states of Maryland and West Virginia and the Small Business Administration (SBA). Dr. Vemuri also helped start several portfolio companies by identifying and sourcing technologies from universities in the Mid-Atlantic region. Prior to joining Toucan, she was an Associate Equity Analyst at SalomonSmithBarney and First Union Securities, where Dr. Vemuri helped those firms cover the specialty pharmaceuticals and healthcare sectors. She currently serves on the Board of Corridor Pharma, Cempra Pharmaceuticals, Immune Control, NuPathe, Arginetix, Inc., and StageMark. She is a Board Observer at Optherion, Immune Control, Protez Pharmaceuticals, Regado Biosciences, Tengion, and Tranzyme Pharma. Dr. Vemuri joined Board of Directors of Argolyn Bioscience, Inc. on June 25, 2007. She served on the Boards of Cellatope and Protez Pharmaceuticals. She is also on the Board of Directors and Executive Committee of Southeast BIO, the Advisory Committee of BioAdvance – the Biotechnology Greenhouse of Southeastern Pennsylvania, and the Selection Committee for the “Best Incubator Company of the Year” awards for companies located in Maryland. Dr. Vemuri is on the Advisory Board of Fox Chase Cancer Center’s Innovation Fund and the Sid Martin Biotechnology Incubator. Dr. Vemuri has been very active in the Mid-Atlantic region’s biotechnology community. Dr. Vemuri is a regularly invited speaker at the Wharton Healthcare Program. Prior to her career in business, Dr. Vemuri worked as a Research Scientist at The Wistar Institute and as a postdoctoral fellow at Thomas Jefferson University. Dr. Vemuri holds a Ph.D. in Biochemistry from Indian Institute of Sciences, an M.B.A. from the Wharton School of the University of Pennsylvania, and a M.S. from Central University, India.

    [ Back to top ]

    Fred Zussa
    Managing Director, Health Digital Ventures, New York, NY

    Mr. Zussa is a Health Tech / HIT venture capital investor seeking early-stage investments opportunities at the intersect of healthcare and information technology. He has 6 years of experience in healthcare through various Corporate and Business Development roles at Pfizer. Strong understanding of market trends and emerging business opportunities. In addition, Fred has achieved 8 years of experience in software engineering at 3 different start-ups in the Silicon Valley and Boston, and at a global technology consultancy. He is a frequent speaker at industries conferences on the subjects of health tech, healthcare transformation, business model innovation, innovation partnering and open innovation.

    [ Back to top ]

     

  • Conference Info:

     

    Date: June 26-27, 2013
    Location: The Metropolitan Club, New York City


    Audience: Institutional investors, high net worth individual investors, family offices, business development executives throughout the US and Europe building and financing high growth medical technology, health care and life science companies.

    View the Schedule!

    View the Agenda!